Printed From:

Toujeo® T2DM Dosing Calculator

Dosing Calculator

Determine a patient's starting dose based on body weight1,a Enter a patient's weight (lbs)—to calculate the recommended starting dose

Weight in pounds

Toujeo® offers 2 pen device options for your patients:

The highest capacity basal insulin pen on the market1-5 with double the maximum injection dose of SoloStar® in a single injection

The SoloStar® pen that your patients know and may use (see study result below)a

The pens also share key features:

  • Same pen size
  • 5-second hold time6,7
  • 42-day shelf life1
  • Lowest injection volume of any basal insulin1-5‡
  • Known SoloStar® platform

*A patient’s dose, if previously an odd number, will need to be adjusted up or down 1 Unit by a healthcare provider if switching from a different pen.

Toujeo Max SoloStar® is recommended for appropriate adult patients who require at least 20 Units of basal insulin per day.

On a unit-for-unit basis.

The highest capacity basal insulin pen on the market1-5:

The larger capacity pen (900 Units) means:

  • Fewer pens to store*
  • Fewer injections for patients requiring greater than 80 Units per dose

*Depending on prescription insurance coverage, using fewer pens per year may allow for fewer refills and associated co-pays.

The Toujeo® SoloStar® pen device:

Key attributes of the Toujeo® SoloStar® pen:

  • 95% of new start basal insulin patients rated Toujeo® SoloStar® as easy to use after training and 4 weeks of use, in a study8,a It is important to train patients on proper product administration
  • Less injection force9*

aStudy Design: Pen- and insulin-naive T2DM patients inadequately controlled on OADs were enrolled in a 4-week, multicenter, open-label, single-arm, phase 3b study to evaluate the ease of use/ease of learning of the Toujeo® SoloStar® pen. On Day 1, patients were trained on use of the device. Only patients who completed the training and demonstrated a successful injection without assistance were eligible for this study (n=40). Toujeo® was injected once-daily in the evening. Patients were titrated to a target SMPG of 80-100 mg/dL. Study limitations: potential bias could have been introduced due to the small population and the study's short duration; however, the study was designed to minimize such bias.8

*Compared with Lantus® SoloSTAR®, FlexPen®, and KwikPen® in a laboratory environment; doses were not delivered into tissue.

Adding Toujeo® Max SoloStar® and Toujeo® SoloStar® to your Electronic Medical Record

How to initiate and titrate Toujeo® to individualized goal

The starting dose of Toujeo® is based on prior treatment1



Weight-based insulin-naive


Once-daily basal


of total daily NPH dose

FPG, fasting plasma glucose; NPH, neutral pH.

ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.

More or less stringent goals may be appropriate for individual patients.10

ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.More or less stringent goals may be appropriate for individual patients.2

In clinical trials, patients started on, or changed to, Toujeo® required a higher dose than patients controlled with Lantus®.

Ensure patients have a prescription for Toujeo® as well as a second, separate prescription for pen needles.

Clinical Profile

Explore the pharmacology and efficacy and safety of Toujeo®

Learn more

Coverage and Savings

See how your patients can save with Toujeo®

See local coverage

References: 1. Toujeo Prescribing Information. 2. Basaglar Prescribing Information. 3. Lantus Prescribing Information. 4. Levemir Prescribing Information. 5. Tresiba Prescribing Information. 6. Toujeo® SoloStar® Instructions for Use. 7. Toujeo® Max SoloStar® Instructions for Use. 8. Pohlmeier H, Berard L, Brulle-Wohlhueter C, et al. J Diabetes Sci Technol. 2016;11(2):263-269. 9. Klonoff D, Nayberg I, Erbstein F, Cali A, Brulle-Wohlhueter C, Haak T. J Diabetes Sci Technol. 2015;9(4):936-938. 10. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.